1612 results about "Genetically modify" patented technology

The invention relates to recombinant escherichia coli THRS-6 and a method for synthesizing L-threonine by using the recombinant escherichia coli THRS-6. The invention belongs to the technical field of bioengineering, and relates to an aspartic acid kinase thrAmut and pyridine nucleotide transhydrogenase pntAB gene derived from escherichia coli, an aspartic acid dehydrogenase aspDH gene derived from pseudomonas aeruginosa, a hemoglobin vgb gene derived from vitreoscilla and a transcriptional regulation factor irrE gene derived from radiococcus. The recombinant escherichia coli is used as a substrate, the ldhA gene is knocked out to further modify the recombinant escherichia coli, the recombinant escherichia coli THRS-6 with glucose as the substrate is obtained, the THRS-6 is used for fermentation, and the yield and conversion rate of the L-threonine are obviously improved.

The invention relates to a gene modified cell and a method for producing fucosyllactose by using the gene modified cell, in particular to a saccharomyces cerevisiae gene modified cell and application thereof, and belongs to the technical field of biological gene engineering. The present invention provides a genetically modified cell comprising a recombinant nucleic acid sequence encoding a polypeptide having an [alpha]-1, 2-fucosyltransferase polypeptide ([alpha]-1, 2-fucosyltransferase) activity. The alpha-1, 2-fucosyltransferase polypeptide includes, but is not limited to, polypeptides having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical amino acid sequences with the amino acid sequences of SEQ ID NO: 1-25. According to the gene modified cell, the fucosyllactose synthesis capability of an original strain is improved.

The invention relates to a gene modified cell and a method for producing fucosyllactose by using the gene modified cell, in particular to a kluyveromyces kluyveromyces gene modified cell and application thereof, and belongs to the technical field of biological gene engineering. The present invention provides a genetically modified cell comprising a recombinant nucleic acid sequence encoding a polypeptide having an [alpha]-1, 2-fucosyltransferase polypeptide ([alpha]-1, 2-fucosyltransferase) activity. The alpha-1, 2-fucosyltransferase polypeptide includes, but is not limited to, polypeptides having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical amino acid sequences with the amino acid sequences of SEQ ID NO: 1-25. According to the gene modified cell, the fucosyllactose synthesis capability of an original strain is improved.

The invention provides a method for genetically modifying bordetella pertussis and application of the method. The method comprises the following steps: knocking down or knocking out a first nutrition screening gene of bordetella pertussis to generate a first auxotrophic cell; replacing the first genetic element with a second nutrition screening gene through recombination treatment to obtain a second auxotroph cell; replacing the second nutritional screening gene with the genetically modified second genetic element through recombination treatment to obtain a third nutritional deficient cell; and restoring the first nutritional screening gene to the genome of the third nutritional deficient cell through recombination treatment. In the modification process, use of antibiotics is not involved, no redundant fragments are introduced except for target modification sites, and the method has the advantages that the genetic background purity is high, and no biological safety risk exists in the modification process.

The invention relates to a recombinant pichia pastoris strain capable of producing astaxanthin at high yield as well as a construction method and application of the recombinant pichia pastoris strain. The recombinant pichia pastoris strain is obtained by expressing ATP (adenosine triphosphate) citrate lyase (ACL) and acetyl-CoA synthase (ACS) or phosphoketolase (PK) and phosphotransacetylase (PTA), choline kinase (CK), inositol polyphosphate kinase (IPK) and vitreoscilla hemoglobin (VHB) in host bacteria. Wherein the host bacterium is a pichia pastoris gene modified strain PP-LC2. The astaxanthin production performance of the recombinant strain is verified on the basis of comparison of precursor supply pathways, IUP pathway construction and improvement of the oxygen supply capacity of the engineering strain, and the astaxanthin production capacity of the pichia pastoris is further improved. The construction method of the recombinant pichia pastoris is simple, the synthesis of astaxanthin can be better promoted, the engineering strain can efficiently synthesize the astaxanthin by utilizing methanol through amplification fermentation of a 5L fermentation tank, and industrial production is facilitated.

The present invention provides a non-human animal expressing a human or chimeric (e.g., humanized) GDF8 protein and methods of use thereof.

The disclosure encompasses genetically modified plants and methods for improving phosphorus redistribution and use efficiency. The genetically modified plants increase the expression of a nonspecific phospholipase C4 (NPC4) protein, enhancing phosphorus remobilization from old, senescing tissues to young, growing tissues and seeds. The genetic modification improves plant growth, increases seed and oil yield, and alters fatty acid composition. The genetically modified plants demonstrate enhanced phosphorus use efficiency under phosphorus-limited conditions, showing greater growth and yield improvements compared to wild-type plants. Specifically in camelina plants, the genetic modification increases seed yield, elevates oil content, and alters fatty acid composition of the oil under P-limited conditions.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The present disclosure provides genetically modified plants, plant cells, or plant tissues wherein the plants, plant cells, or plant tissues comprise an exogenous nucleic acid comprising a nucleotide sequence encoding a 30S ribosomal protein or a homolog thereof, wherein the 30S ribosomal protein or the homolog thereof is expressed in the plant, plant cell, or plant tissue. The current disclosure provides methods of improving drought tolerance and water loss in a plant, plant cell, or plant tissue, the methods comprising an exogenous nucleic acid sequence encoding a 30S ribosomal protein or a homolog thereof, wherein the 30S ribosomal protein or the homolog thereof is expressed in the plant, plant cell, or plant tissue. Additionally, the current disclosure is describes to genetically modified plants, plant cells, or plant tissues wherein the plants, plant cells, or plant tissues comprise an exogenous nucleic acid comprising a nucleotide sequence encoding a cation / H+ exchanger 20 (CHX20) protein or a homolog thereof, wherein the nucleotide sequence is operably linked to a heterologous promoter, and the CHX20 protein or homolog thereof is expressed in the plant, plant cell, or plant tissue. Finally, the current disclosure provides methods of improving drought tolerance and water loss in a plant, plant cell, or plant tissue, the methods comprising an exogenous nucleic acid sequence encoding a CHX20 or a homolog thereof, wherein the CHX20 or the homolog thereof is expressed in the plant, plant cell, or plant tissue.

This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Transgenic rodents and rodent cells that express components of the human immune system, and their uses in generating human T cell receptors (TCRs). A genetically modified rodent comprising a TCR alpha gene locus comprising unrearranged human TCR alpha variable gene segments and a human TCR alpha constant region, and a TCR beta gene locus comprising unrearranged human TCR beta variable gene segments and a human TCR beta constant region. Use of hTCR transgenic rodents to generate antigen-specific CD8+ T cell responses for the discovery of fully human TCR sequences with therapeutic potential.

The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and / or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.

Disclosed herein is a genetically engineered mesenchymal stem cells (MSC) comprising genetic alterations that increase gene expressions for adipogenic differentiation, mitochondrial biogenesis and a brown adipocyte marker. Also disclosed herein is a pharmaceutical composition and use of the pharmaceutical composition for preventing, ameliorating and / or treating a metabolic disorder.

The invention belongs to the technical field of biology, and particularly relates to a genetically modified mesenchymal stem cell as well as a preparation method and application thereof. The invention relates to a gene modified mesenchymal stem cell, the gene modified mesenchymal stem cell is a mesenchymal stem cell of an over-expression SIRT6 gene, and the acquisition number of the SIRT6 on NCBI (National Center of Biotechnology Information) is NM001193285. The invention finds that SIRT6 is helpful for delaying the cell senescence process and obviously improving the anti-senescence capability of cells by regulating senescence-related genes and proteins.

Aspects of the present disclosure relate to genetically modified plants and / or algae with increased carbon use efficiency as a result of an increased ability for bicarbonate to cross membranes within plant cells. Other aspects of the present disclosure relate to methods of making such plants and / or algae as well as cultivating these genetically modified plants to increase carbon use efficiency and / or growing these genetically modified algae to increase carbon use efficiency.

To provide genetically modified plants capable of inducing root nodulation upon appropriate signaling.SOLUTION: Provided herein is a genetically modified plant comprising NODULE INCEPTION (NIN) and NIN-like protein (NLP) that has been genetically altered to be responsive to cytokinin so that the NIN or NLP protein can induce root nodulation upon an appropriate signaling.SELECTED DRAWING: Figure 4A

The invention relates to a Kluyveromyces cerevisiae gene modified cell containing GDP-mannose dehydratase polypeptide, which can be applied to synthesis of human milk oligosaccharide, and belongs to the field of synthetic biology. According to the technical scheme, the gene modified cell comprises a recombinant nucleic acid sequence for coding a polypeptide with GDP-mannose dehydratase polypeptide (GDP-mannose dehydratase polypeptide) activity. The polypeptide capable of catalyzing the conversion of GDP-mannose into GDP-4-keto-6-deoxymannose comprises a polypeptide of which the amino acid sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 and / or the amino acid sequence of polypeptides M1-M13, wherein the amino acid sequence of the polypeptide is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical to the amino acid sequence of the polypeptides M1-M13. The invention provides a kluyveromyces kluyveromyces genetically modified cell with fucosyllactose synthesis activity.

The invention belongs to the technical field of gene engineering, and particularly discloses a waterlogging-resistant gene Di19 and application thereof in waterlogging-resistant breeding of oilseed rape, the Di19 gene of Essel Russian mustard is transferred into oilseed rape for the first time by utilizing a transgenic technology, and the waterlogging resistance of the obtained transgenic oilseed rape is remarkably improved compared with that of wild type oilseed rape. Therefore, the invention provides a new gene resource for breeding the waterlogging-resistant rape.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

The invention discloses a recombinant pichia pastoris strain with high yield of retinaldehyde as well as a construction method and application of the recombinant pichia pastoris strain. The recombinant pichia pastoris strain is obtained by expressing dehydrogenase Zwf1, phosphate dehydrogenase Gnd2, NADH kinase Pos5 and two copied beta-carotene-15, 15 '-monooxygenase BCMO in host bacteria. Wherein the host bacterium is a pichia pastoris gene modified strain PP-B (Propene Polymer-B). The retinaldehyde production performance of the recombinant strain is verified based on cofactor engineering and the copy number of key enzymes, and the retinaldehyde production capacity of the pichia pastoris is further improved. The recombinant pichia pastoris disclosed by the invention is simple in construction method, can better promote the synthesis of retinol, and is beneficial to industrial production as the engineering strain can efficiently synthesize retinol by using methanol as a unique carbon source through amplification fermentation in a 5L fermentation tank.

The invention discloses a CsACS6 gene and application of the CsACS6 gene to improvement of citrus canker resistance, and relates to the technical field of agricultural biology. The coding sequence of the CsACS6 gene is shown as SEQ ID NO.1, and the protein coded by the CsACS6 gene is ACC synthase. According to the invention, an overexpression vector of the CsACS6 coding sequence is constructed, and an agrobacterium tumefaciens-mediated method is utilized to transform citrus epicotyl, so that the expression level of CsACS6 in transgenic citrus is successfully improved, and a transgenic plant with obviously enhanced citrus canker resistance is obtained; the invention has important application value in canker-resistant breeding of citrus, lays a foundation for genetic breeding of citrus canker resistance, and greatly promotes the development and application of citrus canker-resistant genetic engineering.

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells (e.g., T cells) comprising the CAAR, wherein the CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7). The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7).

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

The invention relates to a genetically modified cell, and belongs to the technical field of biological genetic engineering. The invention provides a genetically modified cell, which contains a heterologous nucleic acid sequence of an alpha-1, 3-fucosyltransferase polypeptide. The alpha-1, 3-fucosyltransferase polypeptide further comprises but is not limited to derived polypeptides M1-M21 of the polypeptide with the amino acid sequence as shown in SEQ ID NO: 1, and compared with the polypeptide as shown in SEQ ID NO: 1, the 3-FL catalytic synthesis capability of the derived polypeptides and the specificity of a catalytic substrate are both improved.

The present invention relates to methods of producing microbubble drug conjugates, viral gene therapy microbubble drug conjugates, and disease-targeting microbubbles, for clinical and preclinical ultrasound-mediated therapeutic and diagnostic applications. It includes methods to produce viral vector gene therapy microbubble drug conjugates with antibody linkers conjugated to lipid shelled microbubbles that both bind to and neutralize viral vectors such that the viral gene therapy can transduce and effect permanent genetic changes only after ultrasound is used to disassociate the viral gene therapy from microbubbles at diseased regions of the body.

The present application relates to systems and methods to generate B cells genetically modified to express selected antibodies. The systems and methods can be used to: eliminate the need for classical vaccination; providing protection against infections available for current vaccination; providing protection against infections when the patient is additionally subjected to immunosuppression; and / or provides benefits provided by therapeutic antibodies, such as in the treatment of autoimmune disorders.

The present invention is in the field of genetically modified enzyme and microorganism comprising such a modified enzyme for the production of raspberry ketone or zingerone. The modified enzyme is a polyketide synthase (PKS) issued or derived from a wild type PKS. The modified PKS has the capability to produce vanillylidene acetone from feruloyl-CoA and / or 4-hydroxybenzalacetone from 4-coumaroyl-CoA in a more effective way as compared to wild type BAS or wild type PmPKS, in particular in recombinant bacteria strains.

The invention discloses a production method of fucosylated oligosaccharide. The core of the method is as follows: the GDP-D-rhamnose is converted into the GDP-L-fucose by using the GDP-D-rhamnose-3, 5-epimerase; the GDP-D-rhamnose is obtained by converting the GDP-D-mannose-4, 6-dehydratase and the GDP-4-keto-6-deoxy D-mannose reductase by taking the GDP-D-mannose as a substrate, and the GDP-D-rhamnose is obtained by taking the GDP-D-mannose as a substrate. The invention relates to a method for producing a fucosylated oligosaccharide, which is characterized in that a GDP-D-mannose-4, 6-dehydratase, a GDP-4-keto-6-deoxyD-mannose reductase, a GDP-D-rhamnose-3, 5-epimerase and a fucosyltransferase are expressed in a genetically modified host cell, and the fucosylated oligosaccharide can be produced by the way mentioned above.

The invention provides a method for reducing water soluble carbohydrate (WSC) in a photosynthetic cells and plants, the method comprising the step of genetically modifying the photosynthetic cells and plants to express a modified oleosin including at least one artificially introduced cysteine to reduce WSC. The applicants have shown that in such cells and plants, there is a strong correlation between reduced WSC and elevated photosynthesis. In addition, WSC is significantly simpler to measure that than the other typically measured characteristics when selecting cells or plants with the most favourable characteristics.

The present disclosure provides a population of CD4IL-10 / CAR cells (autologous or allogeneic single-donor and allogeneic polydonor) generated by genetically modifying CD4+ Tcells to express IL-10 and a chimeric antigen receptor. Further provided are methods of generating the CD4IL-10 / CAR cells and methods of using the CD4IL-10 / CAR cells for immune tolerization, treating GvHD, cell and organ transplantation, cancer, and autoimmune and inflammatory disorders.